Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of a drug called BMS-986368 in adults with Multiple Sclerosis Spasticity. This Phase 2 trial compares three different doses of the drug administered orally against a placebo. The study focuses on participants aged 18 to 70 who have a confirmed diagnosis of multiple sclerosis with spasticity lasting at least 6 months. Participants are randomly assigned to one of four groups three groups receive different doses of BMS-986368, and one group receives a placebo. The drug is given on specified days, though exact dosing schedules are not detailed in the summary. The study is double-blind, meaning neither participants nor most study staff know who receives the active drug or placebo. This treatment phase is planned to last at least 6 weeks, during which various assessments will take place. During the study, participants undergo evaluations including the Modified Ashworth Scale for spasticity, Numeric Rating Scale for spasticity severity, Timed 25-Foot Walk, and other clinical assessments. Blood samples will be collected to measure plasma levels of BMS-986368. Safety is closely monitored up to 16 weeks, including adverse events and withdrawal symptoms. The main outcome measure tracks changes in spasticity score at 6 weeks. Participants progress will be assessed through scheduled visits, and the total participation duration may extend beyond the treatment period for safety follow-up.
Actively Recruiting
This research focuses on hospital employees who face various stressors and may experience psychological stress. It evaluates the TeamTime intervention, designed to strengthen team resilience rather than just individual resilience. The study aims to identify factors that help or hinder the implementation of TeamTime and understand how it affects team resilience over time. The TeamTime intervention has two phases first, team leaders receive training on healthy leadership, resilience, occupational health, psychological empowerment, and management skills including coaching techniques. Next, the teams engage in sessions where they start with self-reflection, assess and prioritize stress, and collaboratively work on solving identified problems. Participants are divided into two groups one receiving TeamTime and a control group with no intervention. Participants will be surveyed at three points baseline, 6 months, and 12 months, using questionnaires measuring individual, team, and organizational resilience as the main outcome. Additional assessments include psychological empowerment, organizational commitment, team collaboration, personality traits, willingness to change, and psychosocial factors. The study runs from March 2024 to November 2026 and tracks changes in resilience and related factors over one year.